Floatz logo

Bosutinib

Uterine Cervical Cancer

Nagla Abdel KarimSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

160 Active assets in the Uterine Cervical Cancer cohort.

Asset / SponsorPhaseRating
Vinorelbine
UNICANCER
Phase 2BBB
Indocyanine Green
Istanbul University
Phase 4BB
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Uganda Cancer Institute
Phase 3B
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3B

View all 50 →

Same molecule, other indications

Bosutinib is also rated in:

glioblastomaDormant
B
Indicative ·
59 / 100
View asset →
chronic myeloid leukemiaDormant
B
Indicative ·
57 / 100
View asset →
Lewy body dementiaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →